NeoImmuneTech, Inc. (950220)
Market Closed
11 Aug, 06:30
KRX SM KRX SM Primary ₩
1,546. 00
+22
+1.4436%
₩
23.73B Market Cap
- P/E Ratio
- Div Yield
141,188 Volume
- Eps
₩ 1,524
Previous Close Want to track 950220 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
950220 closed today higher at ₩1,546, an increase of 1.4436% from yesterday's close, completing a monthly increase of 17.4772% or ₩230. Over the past 12 months, 950220 stock gained 85.3717%.
950220 is not paying dividends to its shareholders.
NeoImmuneTech, Inc. has completed 2 stock splits, with the recent split occurring on Jun 10, 2026.
The company's stock is traded on one exchange.
NeoImmuneTech, Inc. (950220) FAQ
What is the stock price today?
The current price is ₩1,546.00.
On which exchange is it traded?
NeoImmuneTech, Inc. is listed on KRX SM.
What is its stock symbol?
The ticker symbol is 950220.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 23.73B.
Has NeoImmuneTech, Inc. ever had a stock split?
NeoImmuneTech, Inc. had 2 splits and the recent split was on Jun 10, 2026.
NeoImmuneTech, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Luke Yun Suk Oh Ph.D. CEO | KRX SM Exchange | KR8840140006 ISIN |
| United States Country | 82 Employees | - Last Dividend | 10 Jun 2026 Last Split | - IPO Date |
Overview
NeoImmuneTech, Inc., a trailblazer in the biotech sector, is dedicated to advancing the field of immuno-therapeutics with a keen focus on T cell enhancement. Established in 2014 and based in Rockville, Maryland, this clinical-stage company harnesses innovative technologies to tackle some of the most challenging illnesses in oncology and infectious diseases. Through rigorous research and development, NeoImmuneTech aims to unlock the potential of the immune system, empowering it to combat diseases more effectively and improving patient outcomes.
Products and Services
At the heart of NeoImmuneTech's innovative pipeline is NT-I7, a groundbreaking immuno-therapeutic agent that stands as the cornerstone of their product offerings:
- NT-I7: This clinical-stage, long-acting human Interleukin-7 (IL-7) is designed to rejuvenate the immune system by increasing both the number and functionality of T cells. NT-I7 is being developed with the vision of treating a broad range of oncologic (cancer-related) and infectious diseases, showcasing NeoImmuneTech's commitment to addressing unmet medical needs through cutting-edge science.
Contact Information
Address: 2400 Research Blvd.
Phone: 240 801 9065
Website: https://www.neoimmunetech.com
